For the quarter ending 2026-03-31, COCH had $21,512K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -4,351 | -6,586 | -6,482 | -10,688 |
| Depreciation | 73 | 80 | 76 | 146 |
| Interest expense and amortization of debt discount on term loans (related party) | - | 4 | 468 | 1,118 |
| Stock-based compensation for services | 44 | -64 | 152 | - |
| Amortization of prepaid insurance | 227 | 226 | 245 | 493 |
| Stock-based compensation | 239 | 179 | 172 | 306 |
| Loss on offering and change in fair value of private warrant liability | -2,005 | 155 | 339 | - |
| Change in fair value of forward purchase agreement put option liability | - | - | - | 0 |
| Change in fair value of publicly traded warrant liability | 390 | 18 | 33 | -162 |
| Change in fair value of forward purchase agreement warrant liability | 13 | -12 | -64 | -458 |
| Change in fair value of forward purchase agreement warrant liability due to extension | - | 24 | - | - |
| Net change in operating lease (related party) | 55 | 245 | -90 | 51 |
| Change in inventory reserve | 12 | -32 | 58 | 10 |
| Accounts receivable, net | -3 | -1 | -8 | 5 |
| Other receivable | -2 | 0 | -1 | -760 |
| Inventories | -44 | -125 | 110 | -111 |
| Prepaid expenses and other current assets | 121 | -66 | 32 | 42 |
| Accounts payable | -1,220 | 412 | 1,006 | -33 |
| Operating lease liability (related party) | -52 | -240 | 45 | -44 |
| Accrued expenses | 664 | 623 | -96 | 312 |
| Product warranty liability | -78 | -41 | -60 | -60 |
| Other liability | - | -868 | - | - |
| Net cash used in operating activities | -6,061 | -5,685 | -4,331 | -8,185 |
| Purchases of property and equipment | - | 172 | 0 | 7 |
| Deposits on equipment not yet placed in service | - | - | - | 0 |
| Net cash used in investing activities | - | -172 | 0 | -7 |
| Proceeds from issuance of class a common stock under employee stock purchase plan | - | 107 | 0 | 77 |
| Payments on insurance financing loans | 208 | 191 | 167 | 469 |
| Proceeds from the issuance of term loans (related party) | - | 0 | 0 | 10,000 |
| Dividends paid to stockholders of series a preferred stock | - | -1 | 0 | 1,820 |
| Proceeds from exercise of forward purchase agreement warrants | - | 2,953 | 158 | - |
| Proceeds from the sale of common stock associated with forward purchase agreement, net of transaction costs | - | - | - | 0 |
| Payment made for extinguishment of term loans (related party) | - | 0 | 100 | - |
| Proceeds from the issuance of class a common stock and investor warrants from registered direct offering | - | 4,000 | 2,500 | - |
| Proceeds from the issuance of class a common stock, issued pre-funded warrants, and series a warrants | 29,997 | 0 | 210 | 204 |
| Offering costs from the issuance of class a common stock, issued pre-funded warrants, and series a warrants | 2,215 | 768 | - | - |
| Deferred offering costs | - | 62 | - | - |
| Net cash provided by financing activities | 27,574 | 6,040 | 2,601 | 7,992 |
| Effect of exchange rate changes on cash | -1 | 0 | -1 | 4 |
| Net (decrease) increase in cash | 21,512 | 183 | -1,731 | -196 |
| Cash, beginning of period | 3,739 | 3,556 | 5,483 | - |
| Cash, end of period | 25,251 | 3,739 | 3,556 | - |
Envoy Medical, Inc. (COCH)
Envoy Medical, Inc. (COCH)